Tirzepatide produced even larger and dose-dependent weight losses, with many participants losing more than 20% of their body weight, the results that were historically only bariatric surgery achieved
The median follow-up time was 4.8 years (range, 3.110.9 years)
Tirzepatide is not recommended during pregnancy or for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Like Semaglutide, it enhances insulin secretion and slows gastric emptying, but the dual action often leads to even more pronounced effects on blood sugar reduction and weight loss
Your provider can also request a peer-to-peer review, during which they speak directly with a healthcare reviewer or medical director from your insurance company to clarify details and advocate for your case
For most practical purposes this difference is clinically insignificant, but perfectionists should be aware of it